The purpose of this study is to determine whether autologous bone marrow mononuclear cells transplantation after stroke is safe and/or effective to improve neurological outcome.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
12
intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)
intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)
Department of Cerebrovascular Disease, National Cardiovascular Center
Suita, Osaka, Japan
Improvement of NIHSS(National Institute of Health Stroke Scale)
Time frame: 30 days after treatment
Frequency of change for the worse in NIHSS
Time frame: 30 days aftrer treatment
Mean level of mRS (modified Rankin Scale)
Time frame: 30 days after treatment
Frequency of death
Time frame: day 30 after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.